Can molecular cancer signals circulating in blood help us prevent cancer-related deaths?
Breakthroughs in laboratory and data science are increasing interest in blood tests to screen for cancer, with colorectal cancer screening at the forefront of this interest.1 These emerging tests should be judged according to classic criteria—the detection of treatable latent disease, improved outcomes compared with no screening, safety, acceptability, and cost-effectiveness relative to alternative options. Developers of novel colorectal cancer screening blood tests are first seeking regulatory approval in the USA, with plans to expand outside the USA in the future.
